- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04165798
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
KEYMAKER-U01 Master Study: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Either Pembrolizumab in Combination With Chemotherapy or With Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and three substudies. Each substudy will enroll a different population of NSCLC participants.
The goal of this umbrella master protocol is to screen potential participants with NSCLC for enrollment into 1 of 3 substudies. Participants must first enroll in this pembrolizumab master protocol study and undergo screening for NSCLC that will be used to assign them to participation in 1 of 3 pembrolizumab substudies.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The following 3 pembrolizumab substudies will evaluate the efficacy of different investigational agents in combination with pembrolizumab given in sequence or in combination with pembrolizumab PLUS chemotherapy:
- KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naïve Patients with Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A) - NCT04165070
- KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B) - NCT04165083
- KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated with anti-PD-(L)1 Therapy (MK-3475-01C) - NCT04165096
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Toll Free Number
- Phone Number: 1-888-577-8839
- Email: Trialsites@merck.com
Study Locations
-
-
-
Budapest, Hungary, 1121
- Recruiting
- Orszagos Koranyi Pulmonologiai Intezet ( Site 0060)
-
Contact:
- Study Coordinator
- Phone Number: +3613913364
-
-
Gyor-Moson-Sopron
-
Gyor, Gyor-Moson-Sopron, Hungary, 9024
- Recruiting
- Petz Aladar Megyei Oktato Korhaz ( Site 0062)
-
Contact:
- Study Coordinator
- Phone Number: +3696418244
-
-
Jasz-Nagykun-Szolnok
-
Szolnok, Jasz-Nagykun-Szolnok, Hungary, 5000
- Recruiting
- Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház ( Site 0061)
-
Contact:
- Study Coordinator
- Phone Number: +36209323256
-
-
-
-
-
Beer-Sheva, Israel, 8457108
- Completed
- Soroka Medical Center ( Site 0072)
-
Haifa, Israel, 3109601
- Recruiting
- Rambam Health Care Campus-Oncology ( Site 0076)
-
Contact:
- Study Coordinator
- Phone Number: 972-4-7776735
-
Jerusalem, Israel, 9103102
- Recruiting
- Shaare Zedek Medical Center ( Site 0075)
-
Contact:
- Study Coordinator
- Phone Number: +972587040620
-
Kfar-Saba, Israel, 4428132
- Recruiting
- Meir Medical Center ( Site 0071)
-
Contact:
- Study Coordinator
- Phone Number: +97297472414
-
Petah Tikva, Israel, 4941492
- Recruiting
- Rabin Medical Center ( Site 0074)
-
Contact:
- Study Coordinator
- Phone Number: +97239378101
-
Ramat Gan, Israel, 5262000
- Recruiting
- Chaim Sheba Medical Center ( Site 0070)
-
Contact:
- Study Coordinator
- Phone Number: +97235307096
-
Tel Aviv, Israel, 64239
- Recruiting
- Sourasky Medical Center ( Site 0077)
-
Contact:
- Study Coordinator
- Phone Number: +972-3-6973082
-
-
-
-
-
Milano, Italy, 20132
- Recruiting
- IRCCS Ospedale San Raffaele ( Site 0171)
-
Contact:
- Study Coordinator
- Phone Number: +390226436627
-
-
Firenze
-
Florence, Firenze, Italy, 50134
- Recruiting
- Azienda Ospedaliera Universitaria Careggi ( Site 0173)
-
Contact:
- Study Coordinator
- Phone Number: +393209225506
-
-
Lazio
-
Roma, Lazio, Italy, 00168
- Recruiting
- Policlinico Gemelli di Roma ( Site 0174)
-
Contact:
- Study Coordinator
- Phone Number: +390630155202
-
-
-
-
-
Seoul, Korea, Republic of, 03722
- Recruiting
- Severance Hospital ( Site 0080)
-
Contact:
- Study Coordinator
- Phone Number: 82022281004
-
Seoul, Korea, Republic of, 06351
- Recruiting
- Samsung Medical Center ( Site 0082)
-
Contact:
- Study Coordinator
- Phone Number: +82215993114
-
-
Kyonggi-do
-
Seongnam-si, Kyonggi-do, Korea, Republic of, 13620
- Recruiting
- Seoul National University Bundang Hospital ( Site 0081)
-
Contact:
- Study Coordinator
- Phone Number: +82215883369
-
-
-
-
Mazowieckie
-
Warszawa, Mazowieckie, Poland, 02-781
- Recruiting
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier
-
Contact:
- Study Coordinator
- Phone Number: +48225463066
-
-
Pomorskie
-
Gdańsk, Pomorskie, Poland, 80-952
- Recruiting
- Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)
-
Contact:
- Study Coordinator
- Phone Number: +48583492979
-
-
Zachodniopomorskie
-
Koszalin, Zachodniopomorskie, Poland, 75-581
- Active, not recruiting
- Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0152)
-
-
-
-
Barcelona
-
Hospitalet de Llobregat, Barcelona, Spain, 08907
- Recruiting
- ICO L Hospitalet ( Site 0090)
-
Contact:
- Study Coordinator
- Phone Number: +34605431976
-
-
Madrid
-
Pozuelo de Alarcon, Madrid, Spain, 28223
- Recruiting
- Hospital Universitario Quiron Madrid ( Site 0091)
-
Contact:
- Study Coordinator
- Phone Number: +34914521987
-
-
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Recruiting
- Banner MD Anderson Cancer Center ( Site 0001)
-
Contact:
- Study Coordinator
- Phone Number: 480-256-3425
-
-
California
-
Duarte, California, United States, 91010
- Completed
- City of Hope ( Site 0014)
-
San Francisco, California, United States, 94158
- Completed
- UCSF Medical Center at Mission Bay ( Site 0007)
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Recruiting
- Georgetown University ( Site 0036)
-
Contact:
- Study Coordinator
- Phone Number: 202-444-2223
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536-0293
- Recruiting
- University of Kentucky Markey Cancer Center ( Site 0019)
-
Contact:
- Study Coordinator
- Phone Number: 859-218-0131
-
-
Maryland
-
Baltimore, Maryland, United States, 21237
- Recruiting
- MedStar Franklin Square Medical Center ( Site 0033)
-
Contact:
- Study Coordinator
- Phone Number: 443-777-7364
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital ( Site 0003)
-
Contact:
- Study Coordinator
- Phone Number: 617-724-4000
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Dana Farber Cancer Institute ( Site 0002)
-
Contact:
- Study Coordinator
- Phone Number: 617-632-4767
-
-
Nebraska
-
Omaha, Nebraska, United States, 68130
- Recruiting
- Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031)
-
Contact:
- Study Coordinator
- Phone Number: 402-691-6971
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03766
- Recruiting
- Dartmouth Hitchcock Medical Center ( Site 0016)
-
Contact:
- Study Coordinator
- Phone Number: 603-650-4428
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Completed
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0037)
-
-
New York
-
New York, New York, United States, 10016
- Recruiting
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0034)
-
Contact:
- Study Coordinator
- Phone Number: 929-455-2428
-
-
North Dakota
-
Fargo, North Dakota, United States, 58102
- Recruiting
- Sanford Fargo Medical Center ( Site 0039)
-
Contact:
- Study Coordinator
- Phone Number: 701-234-2358
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic ( Site 0006)
-
Contact:
- Study Coordinator
- Phone Number: 216-636-6888
-
Columbus, Ohio, United States, 43210
- Recruiting
- Ohio State University Comprehensive Cancer Center ( Site 0015)
-
Contact:
- Study Coordinator
- Phone Number: 614-366-0233
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Abramson Cancer Center of the University of Pennsylvania ( Site 0010)
-
Contact:
- Study Coordinator
- Phone Number: 215-220-9703
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57104
- Recruiting
- Sanford Cancer Center ( Site 0038)
-
Contact:
- Study Coordinator
- Phone Number: 605-328-8000
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas MD Anderson Cancer Center ( Site 0009)
-
Contact:
- Study Coordinator
- Phone Number: 713-792-6363
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Has histologically- or cytologically-confirmed diagnosis of Stage IV squamous or nonsquamous NSCLC
- Participants with nonsquamous NSCLC who are not eligible for an approved targeted therapy
- Is able to to provide archival tumor tissue sample collected either within 5 years or within the interval from completion of last treatment but before entering the screening period or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated obtained within 90 days of treatment initiation
- Has not received prior systemic treatment for their metastatic NSCLC
- Is able to complete all screening procedures within the 35-day screening window
- Has adequate organ function within 10 days of initiation of study treatment
- Male participants must agree to use contraception and should refrain from donating sperm during the treatment period and:
- Substudy 1: for at least 120 days after the last dose of pembrolizumab and for at least 180 days after the last dose of chemotherapy
- Substudies 2 and 3: for at least 120 days after study treatments
Female participants must not be pregnant or breastfeeding, and at least 1 of the following conditions apply:
- Not a woman of childbearing potential (WOCBP), OR
- A WOCBP who agrees to use contraception during the treatment period and:
- Substudy 1: for at least 120 days after the last dose of pembrolizumab and for at least 180 days after the last dose of chemotherapy.
Substudies 2 and 3: for at least 120 days after study treatment
*Substudies 1 and 2 Only:
Has not received prior systemic treatment for their metastatic NSCLC
*Substudy 2 Only:
Has a programmed death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥1%
*Substudy 3 Only:
- Has progressed on treatment with an anti-PD-(L)1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies
- Has progressive disease during/after platinum doublet chemotherapy
Exclusion Criteria:
- Has a diagnosis of small cell lung cancer
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study treatment
- Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has an active autoimmune disease that has required systemic treatment in the past 2 years
- Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- Has an active infection requiring systemic therapy
- Has clinically significant cardiac disease, including unstable angina, acute myocardial infarction within 6 months from Day 1 of study treatment administration, or New York Heart Association Class III or IV congestive heart failure
- Has a known history of HIV infection
- Has a known history of Hepatitis B or known active Hepatitis C virus infection
- Has had major surgery <3 weeks before the first dose of study treatment
- Is expected to require any other form of antineoplastic therapy while on study
- Has received prior radiation therapy to the lung that is >30 Gray (Gy) within 6 months of the first dose of study treatment
- Has received a live vaccine within 30 days before the first dose of study treatment. Any licensed COVID-19 vaccine (including for Emergency Use) in a particular country is allowed as long as they are messenger ribonucleic acid (mRNA) vaccines, adenoviral vaccines, or inactivated vaccines. Investigational vaccines (ie, those not licensed or approved for Emergency Use) are not allowed
- Has received any prior immunotherapy and was discontinued from that treatment due to a severe or worse immune-related adverse event (irAE)
- Has had chemotherapy or biological cancer therapy within 4 weeks before the first dose of study treatment or has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or better from the AEs due to cancer therapeutics administered more than 4 weeks before the first dose of study treatment (including participants who had previous immunomodulatory therapy with residual irAEs)
- Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study treatment
- Previously had a severe hypersensitivity reaction to treatment with monoclonal antibodies (including pembrolizumab) and/or any of their excipients
- Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment
Has had an allogenic tissue/solid organ transplant
*Substudy 1 Only:
- Has symptomatic ascites or pleural effusion (if receiving pemetrexed)
- Has a history or current evidence of a gastrointestinal (GI) condition (e.g. inflammatory bowel disease, Crohn's disease, ulcerative colitis) or impaired liver function or diseases that in the opinion of the investigator may significantly alter the absorption or metabolism of oral medications
- Is getting chemotherapy and has clinically active diverticulitis, intra-abdominal abscess, GI obstruction, or peritoneal carcinomatosis
- Has preexisting neuropathy that is moderate in intensity
- Is unable to interrupt aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs), other than aspirin dose less than or equal to 1.3 gm/day for a 5-day period (8-day period for long acting agents such as peroxicam), for participants who will receive pemetrexed
- Is unable or unwilling to take folic acid or vitamin B12 supplementation, for participants who will receive pemetrexed
Has a known sensitivity to any component of carboplatin, paclitaxel, pemetrexed or any of their excipients
*Substudies 1 and 2 Only:
- Has received prior systemic cytotoxic chemotherapy or other targeted or biological antineoplastic therapy for metastatic disease
Has received prior therapy with an anti-programmed cell death-1 (PD-1), anti-programmed cell death-ligand 1 (PD-L1), or anti-PD-L2 agent or prior therapy targeting other immunoregulatory receptors or mechanisms
*Substudy 3 Only:
- Has received prior therapy targeting other immuno-regulatory receptors or mechanisms, not including anti-PD-(L)1 agents
- Has participated in Substudies 1 or 2
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Prospective NSCLC Participants
Male and female participants with histologically-confirmed diagnosis of squamous or nonsquamous NSCLC will be screened for participation in 1 of 3 pembrolizumab substudies.
|
Participants will undergo tumor imaging using either a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.
Participants without archival tumor tissue samples will undergo tumor tissue collection for newly obtained tumor tissue.
Participants will have blood samples drawn for analysis of:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Programmed Cell Death-Ligand 1 (PD-L1) Tumor Expression Level: Tumor Proportion Score (TPS) <1% vs. TPS =1%
Time Frame: Up to approximately 1 month
|
Participants' tumors will be evaluated for their PD-L1 tumor expression level using archival tumor tissue samples or newly obtained tumor tissue.
The percentage of participants who have a Tumor Proportion Score (TPS) <1% vs. a TPS =1% will be presented.
|
Up to approximately 1 month
|
Tumor Histology Status: Squamous Non-small Cell Lung Cancer (NSCLC) vs. Nonsquamous NSCLC
Time Frame: Up to approximately 1 month
|
Participants' tumors will be evaluated for their tumor histology status as being either squamous vs. nonsquamous NSCLC using archival or newly obtained tumor tissue samples.
The percentage of participants who have squamous vs. nonsquamous NSCLC will be presented.
|
Up to approximately 1 month
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Medical Director, Merck Sharp & Dohme LLC
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3475-U01
- MK-3475-U01 (Other Identifier: Merck)
- KEYMAKER-U01 (Other Identifier: Merck)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Non-Small-Cell Lung
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IA...United States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...United States
-
National Cancer Institute (NCI)Active, not recruitingLung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Puerto Rico
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Society of Thoracic RadiologyActive, not recruitingStage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
Clinical Trials on Tumor Imaging
-
John YuBlaze Bioscience Inc.RecruitingCentral Nervous System TumorUnited States
-
Groupe Hospitalier Paris Saint JosephActive, not recruitingCancer | Lung | Tobacco | Screening | PsychologyFrance
-
Medical University of ViennaUnknownNon-melanocytic Skin Tumors | Melanocytic Skin TumorsAustria
-
Sunnybrook Health Sciences CentreMOUNT SINAI HOSPITAL; Princess Margaret Hospital, Canada; Trillium Health PartnersRecruiting
-
Cedars-Sinai Medical CenterActive, not recruiting
-
University of Missouri-ColumbiaCompleted
-
M.D. Anderson Cancer CenterRecruitingBrain LesionUnited States
-
University Hospital TuebingenRecruiting
-
Turku University HospitalUniversity of HelsinkiRecruitingHigh Grade Serous Carcinoma | High Grade Ovarian Serous AdenocarcinomaFinland
-
Eyenuk, Inc.Completed